202 related articles for article (PubMed ID: 31727244)
1. Enzyme activity of circulating CD73 in human serum.
Morello S; Turiello R; Madonna G; Pinto A; Ascierto PA; Capone M
Methods Enzymol; 2019; 629():257-267. PubMed ID: 31727244
[TBL] [Abstract][Full Text] [Related]
2. Measurement of CD73 enzymatic activity using luminescence-based and colorimetric assays.
Allard B; Cousineau I; Spring K; Stagg J
Methods Enzymol; 2019; 629():269-289. PubMed ID: 31727245
[TBL] [Abstract][Full Text] [Related]
3. Targeting the CD73-adenosine axis in immuno-oncology.
Allard D; Chrobak P; Allard B; Messaoudi N; Stagg J
Immunol Lett; 2019 Jan; 205():31-39. PubMed ID: 29758241
[TBL] [Abstract][Full Text] [Related]
4. Autocrine Adenosine Regulates Tumor Polyfunctional CD73
Gourdin N; Bossennec M; Rodriguez C; Vigano S; Machon C; Jandus C; Bauché D; Faget J; Durand I; Chopin N; Tredan O; Marie JC; Dubois B; Guitton J; Romero P; Caux C; Ménétrier-Caux C
Cancer Res; 2018 Jul; 78(13):3604-3618. PubMed ID: 29559470
[TBL] [Abstract][Full Text] [Related]
5. Targeting the Immunomodulatory CD73/Adenosine System to Improve the Therapeutic Gain of Radiotherapy.
de Leve S; Wirsdörfer F; Jendrossek V
Front Immunol; 2019; 10():698. PubMed ID: 31024543
[TBL] [Abstract][Full Text] [Related]
6. [Immune regulation via the generation of extracellular adenosine by CD73].
Tsukamoto H
Seikagaku; 2014 Dec; 86(6):766-9. PubMed ID: 25675814
[No Abstract] [Full Text] [Related]
7. The therapeutic potential of targeting CD73 and CD73-derived adenosine in melanoma.
Soleimani A; Farshchi HK; Mirzavi F; Zamani P; Ghaderi A; Amini Y; Khorrami S; Mashayekhi K; Jaafari MR
Biochimie; 2020 Sep; 176():21-30. PubMed ID: 32585229
[TBL] [Abstract][Full Text] [Related]
8. Generation and Function of Non-cell-bound CD73 in Inflammation.
Schneider E; Rissiek A; Winzer R; Puig B; Rissiek B; Haag F; Mittrücker HW; Magnus T; Tolosa E
Front Immunol; 2019; 10():1729. PubMed ID: 31404305
[TBL] [Abstract][Full Text] [Related]
9. Ecto-5'-nucleotidase/CD73 contributes to the radiosensitivity of T24 human bladder cancer cell line.
Dietrich F; Figueiró F; Filippi-Chiela EC; Cappellari AR; Rockenbach L; Tremblay A; de Paula PB; Roesler R; Filho AB; Sévigny J; Morrone FB; Battastini AMO
J Cancer Res Clin Oncol; 2018 Mar; 144(3):469-482. PubMed ID: 29305710
[TBL] [Abstract][Full Text] [Related]
10. Correlation of low CD73 expression on synovial lymphocytes with reduced adenosine generation and higher disease severity in juvenile idiopathic arthritis.
Botta Gordon-Smith S; Ursu S; Eaton S; Moncrieffe H; Wedderburn LR
Arthritis Rheumatol; 2015 Feb; 67(2):545-54. PubMed ID: 25418634
[TBL] [Abstract][Full Text] [Related]
11. Serum CD73 is a prognostic factor in patients with metastatic melanoma and is associated with response to anti-PD-1 therapy.
Turiello R; Capone M; Giannarelli D; Morretta E; Monti MC; Madonna G; Mallardo D; Festino L; Azzaro R; Levesque MP; Imhof L; Weide B; Amaral T; Chevrier M; Sucker A; Rutkowski P; Schadendorf D; Lebbe C; Luke JJ; Wistuba-Hamprecht K; Dummer R; Pinto A; Morello S; Ascierto PA
J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33361405
[TBL] [Abstract][Full Text] [Related]
12. The metabolic milieu in melanoma: Role of immune suppression by CD73/adenosine.
Passarelli A; Tucci M; Mannavola F; Felici C; Silvestris F
Tumour Biol; 2019 Apr; 42(4):1010428319837138. PubMed ID: 30957676
[TBL] [Abstract][Full Text] [Related]
13. Ecto-5'-nucleotidase/CD73 enhances endothelial barrier function and sprouting in blood but not lymphatic vasculature.
Yegutkin GG; Auvinen K; Rantakari P; Hollmén M; Karikoski M; Grénman R; Elima K; Jalkanen S; Salmi M
Eur J Immunol; 2015 Feb; 45(2):562-73. PubMed ID: 25402681
[TBL] [Abstract][Full Text] [Related]
14. Dual Mechanisms of Novel CD73-Targeted Antibody and Antibody-Drug Conjugate in Inhibiting Lung Tumor Growth and Promoting Antitumor Immune-Effector Function.
Jin R; Liu L; Xing Y; Meng T; Ma L; Pei J; Cong Y; Zhang X; Ren Z; Wang X; Shen J; Yu K
Mol Cancer Ther; 2020 Nov; 19(11):2340-2352. PubMed ID: 32943546
[TBL] [Abstract][Full Text] [Related]
15. Aberrant circulating levels of purinergic signaling markers are associated with several key aspects of peripheral atherosclerosis and thrombosis.
Jalkanen J; Yegutkin GG; Hollmén M; Aalto K; Kiviniemi T; Salomaa V; Jalkanen S; Hakovirta H
Circ Res; 2015 Mar; 116(7):1206-15. PubMed ID: 25645301
[TBL] [Abstract][Full Text] [Related]
16. The first CD73-instructed supramolecular hydrogel.
Wu D; Du X; Shi J; Zhou J; Zhou N; Xu B
J Colloid Interface Sci; 2015 Jun; 447():269-72. PubMed ID: 25524006
[TBL] [Abstract][Full Text] [Related]
17. Exosomal CD73 from serum of patients with melanoma suppresses lymphocyte functions and is associated with therapy resistance to anti-PD-1 agents.
Turiello R; Capone M; Morretta E; Monti MC; Madonna G; Azzaro R; Del Gaudio P; Simeone E; Sorrentino A; Ascierto PA; Morello S
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35273100
[TBL] [Abstract][Full Text] [Related]
18. AMP hydrolysis reduction in blood plasma of breast cancer elderly patients after different treatments.
Gheler FV; Cappellari AR; Renck D; de Souza JB; de Melo RO; Moehlecke BZ; Moriguchi CA; Engroff P; Lambert APF; Rockenbach L; Morrone FB
Mol Cell Biochem; 2021 Oct; 476(10):3719-3727. PubMed ID: 34089473
[TBL] [Abstract][Full Text] [Related]
19. CD73-adenosine: a next-generation target in immuno-oncology.
Allard D; Allard B; Gaudreau PO; Chrobak P; Stagg J
Immunotherapy; 2016 Feb; 8(2):145-63. PubMed ID: 26808918
[TBL] [Abstract][Full Text] [Related]
20. Immunosuppressive activities of adenosine in cancer.
Allard B; Beavis PA; Darcy PK; Stagg J
Curr Opin Pharmacol; 2016 Aug; 29():7-16. PubMed ID: 27209048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
